H.C. Wainwright analyst Brandon Folkes reiterated a Buy rating on Trevi Therapeutics today and set a price target of $21.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Brandon Folkes’s rating is based on Trevi Therapeutics’ promising developments and strategic advancements with their lead product, Haduvio. The company has shown significant progress in its clinical trials, particularly with the Phase 2b CORAL trial for chronic cough associated with idiopathic pulmonary fibrosis (IPF), which has yielded positive topline results. This positions Trevi to potentially be a leader in the treatment of chronic cough conditions.
Furthermore, Trevi is on track to initiate several key studies, including a Phase 3 trial for IPF-related chronic cough and a Phase 2b trial for refractory chronic cough in 2026. The company’s financial health is also robust, with a strong cash position that extends its operational runway into 2028. These factors collectively support the Buy rating, as they indicate a solid foundation for future growth and potential market leadership.
In another report released today, Needham also maintained a Buy rating on the stock with a $22.00 price target.